Table 4.

Parameters Reported to Correlate with Clinical Outcomes after HCT

Parameter (Ref.)	Timing	Result	Outcome	Multivariate Analysis
Lymphocyte count 813, 814, 815	Day 15	<500/μL	Decreased OS and PFS (autologous HCT)	Yes
Lymphocyte count 816, 817	Day 30	<300/μL	Decreased OS and LFS, Increased NRM (allogeneic HCT)	Yes
B cells and monocyte counts [818]	Day 80	Low (cutoff value not given)	Increased infections	Yes
CD4 T cell count [59]	3 months	<200/μL	Decreased OS, Increased NRM and infections	Yes (OS and NRM), No (infections)
CD8 T cell and B cell counts [819]	6 months	Low (cutoff value not given)	Increased treatment failure (death, relapse or graft failure)	No
CMV peptide–specific CD8 T cell counts∗ [820]	Every 2 weeks during days 0 to 65	<7 cells/mL in all samples	Increased risk of recurrent or persistent CMV reactivation	Not specified
CMV-specific lymphoproliferation [248]	4 months	Undetectable proliferation	Increased late CMV disease	No
NK-cell chimerism [817]	First 100 days	Incomplete chimerism	Decreased RFS	Yes
NK-cell count [821]	Day 15	<80/μL	Decreased OS and PFS (autologous HCT)	Yes
CD56high NK-cell count [822]	Day 14	<7/μL†	Decreased OS, increased NRM	Yes (OS), No (NRM)
Non-HLA genetics 823, 824, 825, 826	Pretransplant	At risk allele in donor or recipient	Increased infections, survival	No

OS indicates overall survival; PFS, progression-free survival; LFS, leukemia-free survival; NRM, nonrelapse mortality; CMV, cytomegalovirus; HCT, hematopoietic cell transplant.

Adapted from Geddes et al. [811] with publisher's permission. Additional studies are needed before any one of the immune tests presented here can be recommended for use in decision making on infection prophylaxis (see text).

^∗Assay measuring the quantity but not quality of CMV-specific T cells.

^†Patients were split into low, intermediate, and high groups with cutoffs of 4/μL and 9/μL.